TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
Frequently asked questions
What sector does TaiwanJ Pharmaceuticals Co., Ltd. (6549) operate in?
TaiwanJ Pharmaceuticals Co., Ltd. belongs to the Other sector and operates in the Biotechnology industry.
What is TaiwanJ Pharmaceuticals Co., Ltd. (6549) current stock price?
As of the latest data, TaiwanJ Pharmaceuticals Co., Ltd. stock price is NT$7.03, with a previous close of NT$6.99. TaiwanJ Pharmaceuticals Co., Ltd. gained NT$0.04 in the last trading session, representing a 0.57% increase.
What is TaiwanJ Pharmaceuticals Co., Ltd. (6549) current market capitalization?
TaiwanJ Pharmaceuticals Co., Ltd. market cap is approximately 563.26 million.
What is TaiwanJ Pharmaceuticals Co., Ltd. (6549) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.30.
Does TaiwanJ Pharmaceuticals Co., Ltd. (6549) pay dividends?
No. TaiwanJ Pharmaceuticals Co., Ltd. does not pay a dividend.
What is TaiwanJ Pharmaceuticals Co., Ltd. (6549) beta (volatility) score?
TaiwanJ Pharmaceuticals Co., Ltd. has a beta of -1.006, indicating lower volatility than the overall market.
